These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3033246)

  • 1. Opioid agonist and antagonist activities of monofunctional nitrogen mustard analogues of beta-chlornaltrexamine.
    Schoenecker JW; Takemori AE; Portoghese PS
    J Med Chem; 1987 May; 30(5):933-5. PubMed ID: 3033246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of naltrexone-derived affinity labels with nonequilibrium opioid agonist and antagonist activities. Evidence for the existence of different mu receptor subtypes in different tissues.
    Sayre LM; Larson DL; Takemori AE; Portoghese PS
    J Med Chem; 1984 Oct; 27(10):1325-35. PubMed ID: 6090663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of C-6 chirality in conferring irreversible opioid antagonism to naltrexone-derived affinity labels.
    Sayre LM; Larson DL; Fries DS; Takemori AE; Portoghese PS
    J Med Chem; 1983 Sep; 26(9):1229-35. PubMed ID: 6310111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
    Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
    J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alkylation of opioid receptor subtypes by alpha-chlornaltrexamine produces concurrent irreversible agonistic and irreversible antagonistic activities.
    Sayre LM; Takemori AE; Portoghese PS
    J Med Chem; 1983 Apr; 26(4):503-6. PubMed ID: 6300401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid agonist affinity in the guinea-pig ileum and mouse vas deferens.
    Porreca F; LoPresti D; Ward SJ
    Eur J Pharmacol; 1990 Apr; 179(1-2):129-39. PubMed ID: 2163849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diprenorphine has agonist activity at opioid kappa-receptors in the myenteric plexus of the guinea-pig ileum.
    Traynor JR; Corbett AD; Kosterlitz HW
    Eur J Pharmacol; 1987 May; 137(1):85-9. PubMed ID: 3038579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological activity of analogues of beta-chlornaltrexamine and beta-funaltrexamine at opioid receptors.
    Portoghese PS; Rein MD; Takemori AE
    J Med Chem; 1986 Oct; 29(10):1861-4. PubMed ID: 3020245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chloroxymorphamine, and opioid receptor site-directed alkylating agent having narcotic agonist activity.
    Caruso TP; Takemori AE; Larson DL; Portoghese PS
    Science; 1979 Apr; 204(4390):316-8. PubMed ID: 86208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans.
    Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB
    J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the receptor selectivity of opioid agonists in the guinea-pig ileum and mouse vas deferens by use of beta-funaltrexamine.
    Hayes AG; Sheehan MJ; Tyers MB
    Br J Pharmacol; 1985 Dec; 86(4):899-904. PubMed ID: 3000501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid receptor activity of GI 87084B, a novel ultra-short acting analgesic, in isolated tissues.
    James MK; Feldman PL; Schuster SV; Bilotta JM; Brackeen MF; Leighton HJ
    J Pharmacol Exp Ther; 1991 Nov; 259(2):712-8. PubMed ID: 1658308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activities of morphinone and N-(cyclopropylmethyl)normorphinone at opioid receptors.
    Fang S; Takemori AE; Portoghese PS
    J Med Chem; 1984 Oct; 27(10):1361-3. PubMed ID: 6207298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological profiles of beta-funaltrexamine (beta-FNA) and beta-chlornaltrexamine (beta-CNA) on the mouse vas deferens preparation.
    Ward SJ; Portoghese PS; Takemori AE
    Eur J Pharmacol; 1982 Jun; 80(4):377-84. PubMed ID: 6286325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of opioid receptor agonist dissociation constants with beta-chlornaltrexamine, an irreversible ligand which also displays agonism.
    Leff P; Dougall IG
    Br J Pharmacol; 1988 Sep; 95(1):234-40. PubMed ID: 2851350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved assays for the assessment of kappa- and delta-properties of opioid ligands.
    Ward SJ; Portoghese PS; Takemori AE
    Eur J Pharmacol; 1982 Nov; 85(2):163-70. PubMed ID: 6295778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 10-Ketonaltrexone and 10-ketooxymorphone.
    Archer S; Seyed-Mozaffari A; Ward S; Kosterlitz HW; Paterson SJ; McKnight AT; Corbett AD
    J Med Chem; 1985 Jul; 28(7):974-6. PubMed ID: 2409281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of dynorphin-selective Kappa receptors in mouse vas deferens and guinea pig ileum. Spare receptor fraction as a determinant of potency.
    Cox BM; Chavkin C
    Mol Pharmacol; 1983 Jan; 23(1):36-43. PubMed ID: 6135144
    [No Abstract]   [Full Text] [Related]  

  • 19. Activity of N-methyl-alpha- and -beta-funaltrexamine at opioid receptors.
    Mohamed MS; Larson DL; Takemori AE; Portoghese PS
    J Med Chem; 1986 Aug; 29(8):1551-3. PubMed ID: 3016272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irreversible blockage of opioid receptor types by ester homologues of beta-funaltrexamine.
    Schoenecker JW; Takemori AE; Portoghese PS
    J Med Chem; 1986 Oct; 29(10):1868-71. PubMed ID: 3020246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.